Literature DB >> 26428948

Measuring depression in prostate cancer patients: does the scale used make a difference?

C F Sharpley1,2, V Bitsika2, D R H Christie1,3, M S Hunter4.   

Abstract

This study investigated differences in the scores, relative severity and major depressive disorder (MDD) and subsyndromal depression status from three standardised self-report scales for depression in prostate cancer (PCa) patients. The Hospital Anxiety and Depression Scale Depression subscale (HADS-D), the Self-rating Depression Scale (SDS) and the Patient Health Questionnaire (PHQ-9) for depression were administered to a sample of 138 PCa patients via mail-out self-reports in Queensland, Australia during May 2014. Despite significant correlations between the total scores from the three scales, severity classification differed across the three scales and there was evidence of considerable underestimation of depression by the HADS-D compared to the PHQ-9, and a similar tendency for the SDS. When patients were classified as fulfilling the criteria for Subsyndromal Depression on the PHQ-9, there were statistically significant differences in the proportion of patients who met those criteria using the HADS-D and the SDS, with large underestimation also present for these two scales. Scale construction and depression items included can produce different results across scales, making inter-study comparisons difficult. Implications for research and clinical practice are described.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  assessment; cancer; depression; prostate

Mesh:

Year:  2015        PMID: 26428948     DOI: 10.1111/ecc.12393

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  1 in total

1.  The prevalence of psychological disorders among cancer patients during the COVID-19 pandemic: A meta-analysis.

Authors:  Lemeng Zhang; Xiaohong Liu; Fei Tong; Ran Zhou; Wanglian Peng; Hui Yang; Feng Liu; Desong Yang; Xufen Huang; Minni Wen; Ling Jiang; Lili Yi
Journal:  Psychooncology       Date:  2022-08-11       Impact factor: 3.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.